Last reviewed · How we verify
Piperacillin-tazobactam combination product
Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections, Nosocomial pneumonia, Febrile neutropenia in immunocompromised patients.
At a glance
| Generic name | Piperacillin-tazobactam combination product |
|---|---|
| Also known as | Tazocin, Zosyn, Piperacillin-Tazobactam |
| Sponsor | Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamases, preventing enzymatic destruction of piperacillin and restoring its activity against beta-lactamase-producing organisms.
Approved indications
- Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections
- Nosocomial pneumonia
- Febrile neutropenia in immunocompromised patients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Phlebitis at injection site
- Headache
- Clostridium difficile-associated diarrhea
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- Aminoglycosides in Early Sepsis (PHASE4)
- Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant (PHASE2)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent (PHASE3)
- Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: